公开(公告)号：US20210275528A1

公开(公告)日：2021-09-09

申请号：US17325900

申请日：2021-05-20

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US11344551B2

公开(公告)日：2022-05-31

申请号：US16776230

申请日：2020-01-29

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20190054088A1

公开(公告)日：2019-02-21

申请号：US16105396

申请日：2018-08-20

Applicant: AbbVie Inc. ,  Neurocrine Biosciences, Inc.

Inventor： Jayanthy Jayanth ,  Kevin C. Spence ,  Gregory A. McClelland ,  Anna V. Stepanenko ,  Kristof Chwalisz ,  Charlotte D. Owens ,  James W. Thomas ,  Jane Castelli-Haley ,  Keith Gordon ,  Michael C. Snabes ,  Ahmed M. Soliman ,  Geoff Zhang ,  David Metzger ,  Yanxia Li ,  Tzuchi R. Ju ,  Xi Shao ,  Oscar Antunez Flores ,  Rita Jain ,  Juki Wing-Keung Ng ,  Janine D. North ,  Hannah Palac ,  Paul M. Peloso ,  Laura A. Williams

IPC: A61K31/513 ,  A61K9/20 ,  A61P15/00 ,  A61P5/30

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

公开(公告)号：US11707464B2

公开(公告)日：2023-07-25

申请号：US17455652

申请日：2021-11-18

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61P15/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/565 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20190209562A1

公开(公告)日：2019-07-11

申请号：US16355326

申请日：2019-03-15

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61P15/00 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61P15/00 ,  A61K2300/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20230285396A1

公开(公告)日：2023-09-14

申请号：US18317725

申请日：2023-05-15

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20220079945A1

公开(公告)日：2022-03-17

申请号：US17455652

申请日：2021-11-18

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20190209563A1

公开(公告)日：2019-07-11

申请号：US16355359

申请日：2019-03-15

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61P15/00 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61P15/00 ,  A61K2300/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

公开(公告)号：US20140288031A1

公开(公告)日：2014-09-25

申请号：US14211096

申请日：2014-03-14

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Wing-Keung Juki K. Ng

IPC: A61K31/513 ,  A61K31/57 ,  A61K31/565

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/57 ,  A61K45/06 ,  A61P15/00 ,  A61K2300/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

Abstract translation: 本发明涉及治疗有或没有子宫肌瘤的受试者的重度月经出血的方法，并且需要通过施用有效量的4 - （（R）-2- [5-（2-氟-3- 甲氧基 - 苯基）-3-（2-氟-6-三氟甲基 - 苄基）-4-甲基-2,6-二氧代-3,6-二氢-2H-嘧啶-1-基] -1-苯基 - 乙基氨基） - 丁酸或其药学上可接受的盐，与雌激素和孕激素组合。

公开(公告)号：US11045470B2

公开(公告)日：2021-06-29

申请号：US16355359

申请日：2019-03-15

Applicant: AbbVie Inc.

Inventor： Kristof Chwalisz ,  Laura A. Williams ,  Rita I. Jain ,  Janine D. North ,  Juki Wing-Keung Ng

IPC: A61K31/513 ,  A61K45/06 ,  A61K31/565 ,  A61K31/57 ,  A61P15/00

Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.